+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07829653

Evaluating Fezolinetant 45 mg Daily for Reducing Moderate to Severe Hot Flashes in Indian Women Experiencing Menopause

Led by Astellas Pharma Inc · Updated on 2026-11-02

100

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating fezolinetant to help reduce hot flashes and night sweats in Indian women going through menopause who experience moderate to severe vasomotor symptoms VMS. Fezolinetant is already approved in many countries, but further studies are needed to confirm its effects in India. This study aims to confirm if fezolinetant can reduce the frequency and severity of hot flashes in this population. Participants will take one tablet of fezolinetant once daily for up to 12 weeks in this single-group study. Before, during, and after treatment, women will use an electronic device or smartphone app to track their hot flashes and night sweats. The study treatment is oral and is given continuously during the treatment period. Women will visit the study clinic several times to provide health information and report on their symptoms. At each visit, researchers will check for any medical problems and monitor safety through laboratory tests and vital signs. After completing the 12-week treatment, there will be a follow-up visit three weeks later. Each participant will take part in the study for about five months, during which researchers will measure changes in the frequency and severity of hot flashes.

CONDITIONS

Brief Title

A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause

Research Team

A

Astellas Pharma Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here